



S/N 09/637,530

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Clifford P. Stanners et al.

Examiner: S. Rawlings, Ph.D.

Serial No.: 09/637,530

Group Art Unit: 1642

Filed: August 11, 2000

Docket: 186.009US1

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

SUPPLEMENTAL PRELIMINARY AMENDMENT

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

NOV 07 2002

TECH CENTER 1600/2900

Sir:

In response to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed June 21, 2002, please amend the above-identified patent application as follows:

H
14/B
K
1/2002

In the Drawings

Please replace Figure 9 with substitute Figure 9 enclosed herewith. The amendments to Figure 9 are shown in red ink on the substitute drawing page.

In the Specification

Please enter the enclosed substitute ~~SEQUENCE LISTING~~ into the specification.

Remarks

This Supplemental Preliminary Amendment and the above-referenced substitute SEQUENCE LISTING are filed in part to conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 - 1.825. In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted substitute SEQUENCE LISTING in ASCII computer readable form is also submitted on even date herewith to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington VA 22202. The contents of the paper version of the substitute SEQUENCE LISTING submitted herewith, and the computer readable form being submitted to Box Sequence, are the same and do not include new matter.

SEQ ID NO:5 was amended to correct a typographical error. SEQ ID NO:5, both amino acids 53 and 54 were amended from "Gly" to "Gln." Support for this amendment can be

09/637,530
11/20/2002 KDO/BJG/EP0000001
01 FC:2254

PRELIMINARY AMENDMENT

Serial Number: 09/637,530

Filing Date: August 11, 2000

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

Page 2

Dkt: 186.009US1

found in Figure 1 of Beauchemin, et al., "Isolation and Characterization of Full-Length Functional cDNA Clones for Human Carcinoembryonic Antigen," Molecular and Cellular Biology, 7(9):3221-3230 (1987; a copy of which is enclosed herewith). No new matter has been added.

Substitute drawing page 10/15 (Figure 9) is enclosed herewith to correct minor typographical errors. No matter has been added.

Respectfully submitted,

CLIFFORD P. STANNERS ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 349-9592

Date Oct. 31, 2002

By Ann M. McCrackin

Ann M. McCrackin
Reg. No. 42,858

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 31 day of October, 2002.

PATRICIA A. HULTMAN

Name

Patricia A. Hultman
Signature